Embla Medical hf.
OSSFF
$4.15
$0.071.72%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 873.51M | 857.82M | 854.89M | 840.30M | 819.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 873.51M | 857.82M | 854.89M | 840.30M | 819.70M |
| Cost of Revenue | 325.53M | 315.79M | 320.19M | 319.17M | 313.15M |
| Gross Profit | 547.98M | 542.03M | 534.70M | 521.13M | 506.55M |
| SG&A Expenses | 385.44M | 381.05M | 381.11M | 376.06M | 370.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 753.89M | 738.39M | 742.14M | 735.17M | 723.23M |
| Operating Income | 119.62M | 119.43M | 112.75M | 105.13M | 96.47M |
| Income Before Tax | 96.35M | 95.24M | 90.56M | 89.85M | 79.72M |
| Income Tax Expenses | 22.62M | 22.55M | 21.60M | 20.49M | 18.46M |
| Earnings from Continuing Operations | 73.73 | 72.69 | 68.96 | 69.36 | 61.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -595.00K | -510.00K | -682.00K | -289.00K | -158.00K |
| Net Income | 73.14M | 72.18M | 68.28M | 69.07M | 61.10M |
| EBIT | 119.62M | 119.43M | 112.75M | 105.13M | 96.47M |
| EBITDA | 147.14M | 146.99M | 141.92M | 128.51M | 119.02M |
| EPS Basic | 0.17 | 0.17 | 0.16 | 0.16 | 0.14 |
| Normalized Basic EPS | 0.14 | 0.14 | 0.13 | 0.13 | 0.12 |
| EPS Diluted | 0.17 | 0.17 | 0.16 | 0.16 | 0.14 |
| Normalized Diluted EPS | 0.14 | 0.14 | 0.13 | 0.13 | 0.12 |
| Average Basic Shares Outstanding | 1.69B | 1.70B | 1.70B | 1.71B | 1.70B |
| Average Diluted Shares Outstanding | 1.69B | 1.70B | 1.70B | 1.71B | 1.70B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |